ArticleOxford open immunology2020
Cholesterol-modifying drugs in COVID-19.
Article in Oxford open immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.Diabetes & metabolism · 2021 · on this mapPooled it
- Development and external validation of an interpretable machine-learning model for HFpEF comorbidity risk in COPD patients.Respiratory research · 2026Article
- Probing SARS-CoV-2 membrane binding peptide via single-molecule AFM-based force spectroscopy.Nature communications · 2025Article
- Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis.Cellular and molecular life sciences : CMLS · 2023Review
- An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.PLoS pathogens · 2023Article
- Sleep and circadian rhythm disruption alters the lung transcriptome to predispose to viral infection.iScience · 2023Article
- The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling.iScience · 2022Article
- Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.Communications biology · 2022Article
- Lipid Raft Integrity and Cellular Cholesterol Homeostasis Are Critical for SARS-CoV-2 Entry into Cells.Nutrients · 2022Article
- Screening Large Population Health Databases for Potential Coronavirus Disease 2019 Therapeutics: A Pharmacopeia-Wide Association Study of Commonly Prescribed Medications.Open forum infectious diseases · 2022Article
- Coronavirus Infection and Cholesterol Metabolism.Frontiers in immunology · 2022Review
- Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2Frontiers in microbiology · 2022Article
- Influence of Co-morbidities During SARS-CoV-2 Infection in an Indian Population.Frontiers in medicine · 2022Article
- Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review.Journal of diabetes and metabolic disorders · 2021Review
- Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469 749 Adults From 2 Canadian Provinces.Journal of the American Heart Association · 2021Article
- Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Circulating Lipids and COVID-19: Insights From Mendelian Randomization.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- 7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19.The Journal of steroid biochemistry and molecular biology · 2021Review
- Inferring the Main Drivers of SARS-CoV-2 Global Transmissibility by Feature Selection Methods.GeoHealth · 2021Article
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could influence the virus-host relationship. Cholesterol is essential for the assembly, replication and infectivity of enveloped virus particles; we highlight several cholesterol-modifying drugs with the potential to alter the SARS-CoV-2 life cycle that could be tested in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.